Challenges in the diagnosis and treatment of neurosarcoidosis. 2015

Claudio Tana, and Susanne Wegener, and Ewa Borys, and Stefan Pambuccian, and Georgi Tchernev, and Marco Tana, and Maria Adele Giamberardino, and Mauro Silingardi
a Internal Medicine Unit , Guastalla Hospital, AUSL Reggio Emilia , Reggio Emilia , Italy.

The diagnosis and treatment of neurosarcoidosis can be very challenging for several reasons. It affects clinically 5%-10% of sarcoidosis patients, but can be found in up to 25% of autopsies. These data reveal that a high percentage of asymptomatic or misdiagnosed cases can be missed at an initial diagnostic approach. Clinical and imaging findings are often non-specific since they can be found in a large number of neurological disorders. Histopathology can also be confounding if not performed by an expert pathologist and not placed in an appropriate clinical context. In this review, we discuss clinical features, laboratory findings, imaging, and histology of neurosarcoidosis, and we report current evidence regarding drug therapy. We conclude that a correct diagnostic approach should include a multidisciplinary evaluation involving clinicians, radiologists, and pathologists and that future studies should evaluate the genetic signature of neurosarcoidosis as they could be helpful in the assessment of this uncommon disease. With head-to-head comparisons of medical treatment for neurosarcoidosis still lacking due to the rarity of the disease and an increasing number of immunomodulating therapies at hand, novel therapeutic approaches are to be expected within the next few years.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D002493 Central Nervous System Diseases Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord. CNS Disease,Central Nervous System Disease,Central Nervous System Disorder,CNS Diseases,Central Nervous System Disorders
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012507 Sarcoidosis An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands. Besnier-Boeck Disease,Boeck's Sarcoid,Besnier-Boeck-Schaumann Syndrome,Boeck Disease,Boeck's Disease,Schaumann Disease,Schaumann Syndrome,Schaumann's Syndrome,Besnier Boeck Disease,Besnier Boeck Schaumann Syndrome,Boeck Sarcoid,Boecks Disease,Boecks Sarcoid,Disease, Schaumann,Sarcoid, Boeck's,Sarcoidoses,Schaumann's Syndromes,Syndrome, Besnier-Boeck-Schaumann,Syndrome, Schaumann,Syndrome, Schaumann's
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D033183 Interdisciplinary Communication Communication, in the sense of cross-fertilization of ideas, involving two or more academic disciplines (such as the disciplines that comprise the cross-disciplinary field of bioethics, including the health and biological sciences, the humanities, and the social sciences and law). Also includes differences in patterns of language usage in different academic or medical disciplines. Communication Research,Cross-Disciplinary Communication,Multidisciplinary Communication,Communication, Cross-Disciplinary,Communication, Interdisciplinary,Communication, Multidisciplinary,Communications, Cross-Disciplinary,Communications, Interdisciplinary,Communications, Multidisciplinary,Cross Disciplinary Communication,Cross-Disciplinary Communications,Interdisciplinary Communications,Multidisciplinary Communications,Research, Communication

Related Publications

Claudio Tana, and Susanne Wegener, and Ewa Borys, and Stefan Pambuccian, and Georgi Tchernev, and Marco Tana, and Maria Adele Giamberardino, and Mauro Silingardi
January 2014, Medicinski pregled,
Claudio Tana, and Susanne Wegener, and Ewa Borys, and Stefan Pambuccian, and Georgi Tchernev, and Marco Tana, and Maria Adele Giamberardino, and Mauro Silingardi
March 2015, Noro psikiyatri arsivi,
Claudio Tana, and Susanne Wegener, and Ewa Borys, and Stefan Pambuccian, and Georgi Tchernev, and Marco Tana, and Maria Adele Giamberardino, and Mauro Silingardi
January 1995, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,
Claudio Tana, and Susanne Wegener, and Ewa Borys, and Stefan Pambuccian, and Georgi Tchernev, and Marco Tana, and Maria Adele Giamberardino, and Mauro Silingardi
May 2022, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
Claudio Tana, and Susanne Wegener, and Ewa Borys, and Stefan Pambuccian, and Georgi Tchernev, and Marco Tana, and Maria Adele Giamberardino, and Mauro Silingardi
November 2021, Neurology(R) neuroimmunology & neuroinflammation,
Claudio Tana, and Susanne Wegener, and Ewa Borys, and Stefan Pambuccian, and Georgi Tchernev, and Marco Tana, and Maria Adele Giamberardino, and Mauro Silingardi
January 2016, Wiadomosci lekarskie (Warsaw, Poland : 1960),
Claudio Tana, and Susanne Wegener, and Ewa Borys, and Stefan Pambuccian, and Georgi Tchernev, and Marco Tana, and Maria Adele Giamberardino, and Mauro Silingardi
June 2012, Presse medicale (Paris, France : 1983),
Claudio Tana, and Susanne Wegener, and Ewa Borys, and Stefan Pambuccian, and Georgi Tchernev, and Marco Tana, and Maria Adele Giamberardino, and Mauro Silingardi
December 2022, Current rheumatology reports,
Claudio Tana, and Susanne Wegener, and Ewa Borys, and Stefan Pambuccian, and Georgi Tchernev, and Marco Tana, and Maria Adele Giamberardino, and Mauro Silingardi
December 2023, Life (Basel, Switzerland),
Claudio Tana, and Susanne Wegener, and Ewa Borys, and Stefan Pambuccian, and Georgi Tchernev, and Marco Tana, and Maria Adele Giamberardino, and Mauro Silingardi
January 1987, Fortschritte der Neurologie-Psychiatrie,
Copied contents to your clipboard!